FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Muscles Ligaments Tendons J / Combined use of platelet rich plasma & micro-fat in spo...
Muscles, ligaments and tendons journal2016; 6(2); 198-204; doi: 10.11138/mltj/2016.6.2.198

Combined use of platelet rich plasma & micro-fat in sport and race horses with degenerative joint disease: preliminary clinical study in eight horses.

Abstract: To assess the safety and potential efficacy of a standardized technique consisting of intra-articular injection of 10 cc of a homogeneous mixed product using autologous micro-fat and platelet rich plasma (PRP) (ratio 1:1) in the carpus or the fetlock joint of sport horses presenting degenerative joint disease (DJD). Methods: Eight sport horses with DJD confirmed by radiography and ultrasonography and causing lameness and the impossibility to compete were treated. PRP was prepared after a double centrifugation whereas micro-fat was harvested and purified using a closed system. The two products were connected and mixed by gentle back and forth shaking of the syringes to finally obtain 10 ml of an homogeneous mixed product. Follow up was performed from 5 to 10 months with assessment of AAEP lameness score and return to training and competition. Results: Nine joints were treated with significant improvement of the AAEP lameness score three months after the procedure (p = 0.021). Four horses returned to official competition between 5 to 10 months after the procedure (7.0±2.5) and three of them resumed intensive training between 5 to 9 months (6.3±2.3). No adverse event occurred. Conclusions: This study is a first step in the development of innovative therapy for DJD which combines the potential chondrogenic differentiation of MSCs inside equine adipose tissue with the proliferative effect of growth factors present in PRP.
Get Full Text
Publication Date: 2016-09-17 PubMed ID: 27900293PubMed Central: PMC5115251DOI: 10.11138/mltj/2016.6.2.198Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research explores the safety and effectiveness of a novel treatment for degenerative joint disease (DJD) in sport and racing horses. It involves the injection of an equal mix of autologous micro-fat and platelet rich plasma (PRP) into the joints of the affected horses.

Objective and Methodology

  • The study aimed to test a new technique for treating DJD in athletic horses. The technique involved injecting a mixture of micro-fat (fat harvested from the same horse) and PRP (a substance rich in growth factors).
  • The researchers used 8 horses diagnosed with DJD, resulting in lameness and their inability to compete in racing or sport.
  • The PRP was prepared after two stages of centrifugation, while micro-fat was collected and purified in a ‘closed’ environment. Both elements were mixed in equal measure and rigorously shaken in syringes to form a uniform mix.
  • The formulated mixture was then conscientiously injected into the carpus or fetlock joints of the horses.
  • To test the efficacy of the treatment, the horses’ American Association of Equine Practitioners (AAEP) lameness scores were monitored for between 5 and 10 months after the treatment.

Results

  • The treatment was administered to nine joints in total. The researchers observed a remarkable improvement in the AAEP lameness scores three months after the treatment was done.
  • Four out of the eight horses that had been unable to compete returned to official competition between 5 and 10 months after being treated. Additionally, three of these four were able to resume intensive training, between 5 and 9 months after the treatment.
  • During the observation period, there were no adverse events or negative outcomes reported.

Conclusion

  • The researchers concluded that this standardised treatment involving the combined use of PRP and micro-fat may be an innovative therapeutic approach for DJD in horses.
  • The therapy seems to harness the chondrogenic differentiation potential of mesenchymal stem cells (MSCs) found in the horses’ adipose tissue, together with the growth-stimulating properties of the PRP factors.

Cite This Article

APA
Bembo F, Eraud J, Philandrianos C, Bertrand B, Silvestre A, Veran J, Sabatier F, Magalon G, Magalon J. (2016). Combined use of platelet rich plasma & micro-fat in sport and race horses with degenerative joint disease: preliminary clinical study in eight horses. Muscles Ligaments Tendons J, 6(2), 198-204. https://doi.org/10.11138/mltj/2016.6.2.198

Publication

Muscles, ligaments and tendons journal
ISSN: 2240-4554
NlmUniqueID: 101600853
Country: Italy
Language: English
Volume: 6
Issue: 2
Pages: 198-204

Researcher Affiliations

Bembo, Fabrizio
  • Veterinary Clinic, Luynes France.
Eraud, Julia
  • Plastic Surgery Department, La Conception University Hospital, Marseille, France.
Philandrianos, Cecile
  • Plastic Surgery Department, La Conception University Hospital, Marseille, France.
Bertrand, Baptiste
  • Plastic Surgery Department, La Conception University Hospital, Marseille, France.
Silvestre, Alain
  • Radiology Department, Bordeaux Merignac Sports Clinic, Merignac, France.
Veran, Julie
  • Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, La Conception University Hospital, Marseille, France.
Sabatier, Florence
  • Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, La Conception University Hospital, Marseille, France.
Magalon, Guy
  • Plastic Surgery Department, La Conception University Hospital, Marseille, France.
Magalon, Jeremy
  • Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, La Conception University Hospital, Marseille, France.

References

This article includes 28 references
  1. Jeffcott LB, Rossdale PD, Freestone J, Frank CJ, Towers Clark PF. An assessment of wastage in thouroughbred racing from conception to 4 years of age.. Equine Vet J 1982;14:185–198.
    pubmed: 7106081
  2. McIlwraith CW. Current concepts in equine degenerative joint disease.. J Am Vet Med Assoc 1982;180:239–250.
    pubmed: 7035425
  3. Frisbie DD. Future directions in treatment of joint disease in horses.. Vet Clin North Am Equine Pract 2005;21:713–724.
    pubmed: 16297729
  4. Malone ED. Managing chronic arthritis.. Vet Clin North Am Equine Pract 2002;18:411–437.
    pubmed: 12516926
  5. Nizolek DJ, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease. A review.. The Cornell veterinarian 1981;71:355–375.
    pubmed: 7032840
  6. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse – a review.. Vet J 2006;171:51–69.
    pubmed: 16427582
  7. Zubrod CJ, Schneider RK. Arthrodesis techniques in horses.. Vet Clin North Am Equine Pract 2005;21:691–711.
    pubmed: 16297728
  8. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, Mc Ilwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis.. J Orthop Res 2009;27:1675–1680.
    pubmed: 19544397
  9. Mc Ilwraith CW, Frisbie DD, Rodkey WG, Kisiday JD, Werpy NM. Evaluation of intra articular mesenchymal stem cells to augment healing of microfractured chondral defects.. Arthroscopy 2011;27:1552–1561.
    pubmed: 21862278
  10. Wike MM, Nydam DV, Nixon AJ. Enhanced early chondrogenesis in articular defects following arthroscopic mesenchymal stem cell implantation in equine model.. J Orthop Res 2007;25:913–925.
    pubmed: 17405160
  11. Frisbie DD, Cross MW, Mc Ilwraith CW. A comparative study of articular cartilage thickness in the stifle of animal species used in human pre-clinical studies compared to articular cartilage thickness in the human knee.. Vet Comp Orthop Traumatol 2006;19:142–146.
    pubmed: 16971996
  12. Bausset O, Giraudo L, Veran J. Formulation and storage of platelet-rich plasma homemade product.. Biores Open Access 2012;1(3):115–123.
    pmc: PMC3559222pubmed: 23516671
  13. Koch TG, Betts DH. Stem cell therapy for joint problems using the horse as clinically relevant model.. Expert Opin Bio Ther 2007;7:1621–1626.
    pubmed: 17961087
  14. Berg L, Koch T, Heerkens T, Bessonov K, Thomsen P. Chondrogenic potential of mesenchymal stromal cells derived from equine bone marrow and umbilical cord blood.. Vet Comp Orthop Traumatol 2009;22:363–370.
    pubmed: 19750290
  15. Spaas JH, Schauwer CD, Cornillie P, Meyer E, Soom AV. Culture and characterization of equine peripheral blood mesenchymal stromal cells.. Vet J 2013;295:107–113.
    pubmed: 22717781
  16. Giai Via A, Frizziero A, Oliva F. Biological properties of mesenchymal stem cells from different sources.. Muscles, Ligaments and Tendons Journal 2012;2(3):154–162.
    pmc: PMC3666517pubmed: 23738292
  17. Spaas JH, Oosterlinck M, Broeckx S, Dumoulin M, Saunders J. Treatment of equine degenerative joint disease with autologous peripheral blood-derived mesenchymal stem cells: a case report.. Vlaams Dierg Tijdschrift 2012;81:11–15.
  18. Broeckx S, Zimmerman M, Crocetti S, Suls M, Mariën T. Regenerative therapies for equine degenerative joint disease: a preliminary study.. PLoS ONE 2014;9(1):e85917.
    pmc: PMC3896436pubmed: 24465787
  19. Zuk PA. ISRN Stem Cells Review Article. Adipose-Derived Stem Cells in Tissue Regeneration: A Review-Hindawi Publishing Corporation.. ISRN Stem Cells 2013.
  20. Alharbi Z, Opländer C, Almakadi S, Fritz A, Vogt M, Pallua N. Conventional vs. micro-fat harvesting: how fat harvesting technique affects tissue-engineering approaches using adipose tissue-derived stem/stromal cells.. J Plast Reconstr Aesthet Surg 2013;66(9):1271–1278.
    pubmed: 23732072
  21. Mishra A, Tummala P, King A, Lee B, Kraus M. Buffered platelet rich plasma enchances mesenchymal stem cells proliferation and chondrogenic differentiation.. Tissue Eng Part C Methods 2009;15:431–435.
    pmc: PMC2819709pubmed: 19216642
  22. Atashi F, Jaconi ME, Pittet-Cuénod B, Modarressi A. Autologous platelet-rich plasma: a biological supplement to enhance adipose-derived mesenchymal stem cell expansion.. Tissue Eng Part C Methods 2015;21(3):253–262.
    pmc: PMC4346379pubmed: 25025830
  23. Rubio-Azpeitia E, Andia I. Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience.. Muscles, Ligaments and Tendons Journal 2014;4(1):52–62.
    pmc: PMC4049651pubmed: 24932448
  24. Nguyen PS, Desouches C, Gay AM, Hautier A, Magalon G. Development of micro-injection as an innovative autologous fat graft technique: the use of adipose tissue as dermal filler.. J Plast Reconstr Aesthet Surg 2012;65(12):1692–1699.
    pubmed: 22749704
  25. Hessel LN, Bosch G, Van Weeren PR, Ionita JC. Equine autologous platelet concentrates: a comparative study between different available systems.. Equine Vet J 2013;47(3):319–325.
    pubmed: 24773596
  26. Anitua E, Sanchez M, Prado R, Orive G, Padilla S. You are not walking alone in the PRP consensus road.. Muscles, Ligaments and Tendons Journal 2014;4(4):471–472.
    pmc: PMC4327358pubmed: 25767786
  27. Dohan Ehrenfest DM, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives.. Muscles, Ligaments and Tendons Journal 2014;4(1):3–9.
    pmc: PMC4049647pubmed: 24932440
  28. Padulo J, Oliva F, Frizziero A, Maffulli N. Basic principles and recommendations in clinical and field science research:2016 update.. Muscles, Ligaments and Tendons Journal 2016;6( 1):1–5.
    pmc: PMC4915447pubmed: 27331026
Subscribe to our newsletter
Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.